ALISCATM-Breast1 study evaluates alisertib in HR-positive, HER2-negative metastatic breast cancer with 150 patients across three dosage groups. Alisertib, an Aurora A kinase inhibitor, is combined ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback